Mara Goldstein
Stock Analyst at Mizuho
(2.85)
# 1,808
Out of 4,966 analysts
77
Total ratings
44.83%
Success rate
8.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $7.90 | +279.75% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.23 | +348.43% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $9.25 | -13.51% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $10.59 | +296.60% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $8.13 | +515.01% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $16.33 | +175.57% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $84.61 | -8.99% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.57 | +345.86% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.04 | +669.23% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.29 | +4,060.89% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $29.86 | +201.41% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $5.74 | -39.02% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.21 | +16,189.59% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $5.75 | +247.83% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $84.12 | +54.54% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $2.04 | -1.96% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.50 | +700.00% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.06 | +15,180.14% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $35.33 | -43.39% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $9.01 | +432.74% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.06 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $6.36 | +120.13% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $7.90
Upside: +279.75%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.23
Upside: +348.43%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $9.25
Upside: -13.51%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $10.59
Upside: +296.60%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $8.13
Upside: +515.01%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $16.33
Upside: +175.57%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $84.61
Upside: -8.99%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.57
Upside: +345.86%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.04
Upside: +669.23%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.29
Upside: +4,060.89%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $29.86
Upside: +201.41%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $5.74
Upside: -39.02%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.21
Upside: +16,189.59%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $5.75
Upside: +247.83%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $84.12
Upside: +54.54%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $2.04
Upside: -1.96%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.50
Upside: +700.00%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.06
Upside: +15,180.14%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $35.33
Upside: -43.39%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $9.01
Upside: +432.74%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $22.06
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $6.36
Upside: +120.13%